FDA clears anticlotting drug Eliquis

The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes and heart attacks.

The agency previously rejected the drug twice, most recently in June, awaiting additional data from company trials.

The FDA cleared the pill for treating the most common type of irregular heartbeat—atrial fibrillation—in patients at risk for strokes or dangerous clots.

About a quarter of all people aged 40 and older develop atrial fibrillation, a condition in which the heart's two upper chambers contract irregularly and don't pump blood efficiently.

Bristol-Myers Squibb shares rose 60 cents, or 2 percent, to $32.50 in after-hours trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers, Pfizer's Eliquis approved in Japan

Dec 26, 2012

Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Anti-clot drug recommended for new approval in EU

Sep 21, 2012

(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

FDA adds new heart warning to Sanofi's Multaq

Dec 19, 2011

Federal health officials have added new safety warnings to the heart rhythm drug Multaq after company studies linked the pill to higher rates of heart attack, stroke and death in a subset of patients.

Recommended for you

FDA to start regulating lab-developed tests

17 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments